The global typhoid fever vaccines market is estimated to be valued at USD 558.6 Mn in 2026 and is expected to reach a value of USD 1,244.0 Mn by 2033 at a CAGR of 12.2% between 2026 and 2033.
Drivers in the typhoid fever vaccines market include the high prevalence rate of typhoid fever in endemic areas, growing number of national immunization programs, and increased financial and infrastructural support from global health organizations like WHO, UNICEF, and Gavi. Higher awareness of vaccine-preventable diseases, better healthcare infrastructure, and government efforts for improving routine vaccination programs keep driving the market forward. Introduction of very effective typhoid conjugate vaccines (TCV), along with higher investment in public health campaigns, will drive market adoption. But poor accessibility to healthcare in distant locations and vaccine delivery issues are expected to be major restraints. There are opportunities available with broader immunization coverage, global funding programs, and adoption of advanced vaccines.
Based on Vaccine Types, Conjugate Vaccines are projected to lead the market with an estimated market share of 57.8% in 2026. The dominant position held by this segment is largely due to their good immunogenicity, sustained protection, excellent safety in infants and children, and high recommendations by the global health bodies. The incorporation of the same in the immunization schedule and the use in government-led vaccination drives further drive the demand.
According to the Route of Administration, the Parenteral category is predicted to command a market share of roughly 72.4% by 2026. The outstanding performance of the Parenteral category is attributed to the superior effectiveness of injectable typhoid conjugate vaccines, ease of integration into the childhood vaccination program, high vaccination rate, and approval of the product by the government and other stakeholders.
Geographically, the Asia Pacific region is expected to dominate the typhoid fever vaccines market with a market share of 47.3% in 2026 due to the high incidence of typhoid fever, government-sponsored vaccination programs, support from international agencies, and growing usage of typhoid conjugate vaccines in South Asian countries. Africa is forecasted to be the leading region, fueled by vaccination programs, increasing awareness regarding waterborne diseases, strengthening healthcare infrastructure, growing international funds, and collaborations among governments and international health agencies for improved accessibility to vaccines.
Prominent Players in the Typhoid Fever Vaccines Market
-
GlaxoSmithKline plc (GSK)
Company Overview
- Headquarters: London, England, United Kingdom
- Establishment Year: 2000
- Employee Strength: Approximately 70,000 employees
- Leadership: Ms. Emma Walmsley, Chief Executive Officer
- Core Services/Products: Vaccines, prescription medicines, infectious disease vaccines, respiratory therapies, immunology products, and pediatric vaccines.
SWOT Analysis
- Strengths
- Most dominant firm in terms of vaccine manufacturing and marketing.
- Global distribution and collaboration with public health bodies.
- Weaknesses
- High dependency on innovations and regulatory procedures.
- Extensive investments in research and development reduce profit margins.
- Opportunities
- Moving into immunization programs in developing nations backed by the government.
- Greater demand for travel vaccines and pediatric vaccines.
- Threats
- High competition among multinational vaccine companies.
- Bargaining power of public health procurement authorities.
-
Sanofi SA
